Australia - English - Department of Health (Therapeutic Goods Administration)

onelife labs pty ltd - tetrahydrocannabinol, quantity: 4 mg/ml; cannabidiol, quantity: 100 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

onelife labs pty ltd - tetrahydrocannabinol, quantity: 2 mg/ml; cannabidiol, quantity: 50 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

onelife labs pty ltd - tetrahydrocannabinol, quantity: 10 mg/ml; cannabidiol, quantity: 100 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

onelife labs pty ltd - tetrahydrocannabinol, quantity: 30 mg/ml; cannabidiol, quantity: 30 mg/ml - oral liquid - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

elixinol wellness (byron bay) pty ltd - hemp seed oil, quantity: 1 g (equivalent: cannabidiol, qty 75 microgram; equivalent: tetrahydrocannabinol, qty 10 microgram) - capsule, soft - excipient ingredients: glycerol; purified water; vanillin; modified food starch; sorbitol - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support general health and wellbeing ; anti-inflammatory/relieve inflammation ; decrease/reduce/relieve symptoms of mild eczema/dermatitis ; maintain/support skin health

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - nabiximols, quantity: 80 mg/ml - spray, solution - excipient ingredients: propylene glycol; peppermint oil; ethanol absolute - sativex is indicated as treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

montu group pty ltd - cannabidiol, quantity: 1 mg/ml; tetrahydrocannabinol, quantity: 20 mg/ml - oil - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

montu group pty ltd - cannabidiol, quantity: 10 mg/ml; tetrahydrocannabinol, quantity: 10 mg/ml - oil - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

montu group pty ltd - cannabidiol, quantity: 100 mg/ml; tetrahydrocannabinol, quantity: 1 mg/ml - oil - excipient ingredients: medium chain triglycerides

Australia - English - Department of Health (Therapeutic Goods Administration)

montu group pty ltd - cannabidiol, quantity: 25 mg/ml; tetrahydrocannabinol, quantity: 25 mg/ml - oil - excipient ingredients: medium chain triglycerides